VJVirtual | Should patients with lung cancer continue IO after completing 2 years of IO?

Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses whether immunotherapy (IO) should be continued after completing two years of IO for patients with thoracic malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.